Pathway Genomics Files IPO Prospectus for OME: The First IBM Watson-Powered Genomic Health App Unveiled at CES

IBM Chairman and CEO Ginni Rometty showcased a new health app developed by Medtronic, based on IBM’s Watson system, at CES (the International Consumer Electronics Show) on Wednesday. The annual CES event attracts more than 170,000 consumers and some of the world’s largest technology companies. Over the past five years, the healthcare industry has garnered significant attention at the show.

Named after IBM founder Thomas J. Watson, the intelligent system was developed primarily to advance the understanding of vocabulary, language, and more complex domains of human knowledge. IBM is currently commercializing Watson, enabling its technology to be applied commercially in industries such as healthcare and finance. The Watson system was primarily developed by the Massachusetts Institute of Technology, the University of Texas, the University of Southern California, Rensselaer Polytechnic Institute, the University at Albany, the University of Trento, the University of Massachusetts, and Carnegie Mellon University.

Cognitive computing is transforming the way people interact with computers. In her keynote address, IBM’s Ginni Rometty described a new era in which consumers can even leverage cognitive computing technologies in their daily lives. Medtronic’s CEO Omar Ishrak also announced the latest progress in its collaboration with IBM to provide solutions for diabetes management.

Medtronic and IBM selected 600 random diabetes patients and performed intelligent computational analysis on data generated from their use of Medtronic’s insulin infusion pumps and glucose monitors. This technology can predict hypoglycemia three hours in advance, providing sufficient time for diabetic patients to take proactive measures to prevent health-threatening events. The app’s algorithm was developed based on 150 million patient-days of blood glucose data collected by Medtronic’s wearable devices.

Glycemic Alert App Interface Screenshot

As shown in the first screenshot, the app includes measurements for exercise duration, blood glucose levels, and recent carbohydrate intake. Below this data is a trend chart of blood glucose levels, which triggers an alert when values fall below a predefined threshold. The second screenshot displays both carbohydrate intake and expenditure values.

Pathway Genomics also plans to release Pathway Genomics OME, an app developed based on the Watson system. This mobile app integrates intelligent computing for precision medicine with deep learning, enabling Pathway Genomics to provide consumers with personalized health information.